Clinical Trials
26 trialsNCT04631744 2026-05-01
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Weill Medical College of Cornell University
Phase 2 Terminated
NCT06341712 2026-03-31
CabOSTar
Ipsen
Phase 2 Terminated
NCT04338269 2026-03-19
CONTACT-03
Hoffmann-La Roche
Phase 3 Terminated
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT06716853 2026-02-09
TEM-GU
Genenta Science
Phase 1/2 Terminated
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT05200143 2024-09-19
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
Providence Health & Services
Phase 2 Terminated
NCT06377722 2024-04-26
Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
Fundacion Oncosur
Phase 2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04300140 2023-10-30
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Aravive, Inc.
Phase 1/2 Terminated
NCT03201250 2023-09-08
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
University of Nebraska
Phase 1/2 Terminated
NCT02036476 2023-05-09
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03729245 2023-04-11
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
Phase 3 Terminated
NCT04442581 2023-04-05
Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
University of Washington
Phase 2 Terminated
NCT02885324 2022-10-06
Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
Indiana University
Phase 2 Terminated
NCT03964337 2022-06-29
SPARC
Duke University
Phase 2 Terminated
NCT04173338 2022-06-14
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Augusta University
Phase 1 Terminated
NCT04230954 2022-06-07
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
University of South Alabama
Phase 2 Terminated
NCT04066595 2021-08-30
CabUC
Johannes Gutenberg University Mainz
Phase 2 Terminated
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03729297 2021-03-12
Cabo ASAP
Radboud University Medical Center
Phase 2 Terminated
NCT02132598 2021-03-10
Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
University of Pittsburgh
Phase 2 Terminated
NCT01703065 2018-12-04
Cabozantinib in Men With Castration-Resistant Prostate Cancer
University of Washington
Phase 2 Terminated
NCT01522443 2018-05-23
COMET-2
Exelixis
Phase 3 Terminated
NCT01428219 2017-12-12
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT01835184 2014-09-25
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Terminated